Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 26;21(7):37.
doi: 10.1007/s11910-021-01119-w.

Central Nervous System Infections in Immunocompromised Patients

Affiliations
Review

Central Nervous System Infections in Immunocompromised Patients

Amy A Pruitt. Curr Neurol Neurosci Rep. .

Abstract

Purpose of review: This article reviews current epidemiologic trends, clinical presentations, and diagnostic strategies for central nervous system (CNS) infections in human immunodeficiency virus-negative (HIV) patients immunocompromised by their underlying disease or by receipt of immunosuppressive or immunomodulating therapies. Three patient groups are considered: (1) cancer patients; (2) hematopoietic or solid organ transplantation recipients; and (3) patients with autoimmune or inflammatory conditions requiring therapies that alter the host immune response.

Recent findings: Clinical presentations, associated neuroimaging, and cerebrospinal fluid (CSF) abnormalities differ between immunocompromised and immunocompetent patients. Infections can trigger the emergence of neurotropic antibodies or inflammatory conditions due to treatment with cancer immunotherapies. Unbiased metagenomic assays to identify obscure pathogens help clinicians navigate the increasing range of conditions affecting the growing population of patients with altered immunity. Awareness of clinical presentations and disease and drug-specific risks is important for early diagnosis and intervention in these often life-threatening infections and their noninfectious mimes.

Keywords: Disease-modifying therapies; Encephalitis; Herpes viruses; Meningitis; Organ transplantation; Progressive multifocal leukoencephalopathy.

PubMed Disclaimer

Conflict of interest statement

The author declares that she has no conflict of interest.

Similar articles

Cited by

References

    1. Sonneville R, Magalhaesa E, Meyfroidt G. Central nervous system infections in immunocompromised patients. Curr Opin Crit Care. 2017;23(2):128–133. doi: 10.1097/MCC.0000000000000397. - DOI - PubMed
    1. Mukerji SS, Ard K, Schaefer PW, Branda JA. Case 32-2020: a 63-year-old man with confusion, fatigue, and garbled speech. N Engl J Med. 2020;383:1578–1586. doi: 10.1056/NEJMcpc2004996. - DOI - PubMed
    1. Stuby J, Herren T, Guidoc SN, Claudiad P, Alain R. Immune checkpoint inhibitor therapy-associated encephalitis: a case series and review of the literature. Swiss Med Wkly. 2020;150:w20377. doi: 10.4414/smw.2020.20377. - DOI - PubMed
    1. Sechi E, Markovic SN, McKeon A, Duby D, et al. Neurologic autoimmunity and immune checkpoint inhibitors autoantibody profiles and outcomes. Neurology. 2020;95:e2442–e2452. doi: 10.1212/WNL.000000000001063. - DOI - PMC - PubMed
    1. Armangue T, Leypoldt F, Malaga I, et al. Herpes simplex virus encephalitis is a trigger of brain autoimmunity. Ann Neurol. 2014;75(2):317–323. doi: 10.1002/ana.24083. - DOI - PMC - PubMed

LinkOut - more resources